炎症和突变负担与尼沃卢马布或伊皮利穆马布联合疗效在结直肠癌中的差异性相关
Ming Lei1, Michael J Overman2, Jin Yao3
1Department of Translational Medicine, Bristol Myers Squibb, Princeton, NJ, USA. Ming.Lei1@bms.com.
Nature communications
|October 6, 2025
概括
生物标志物预测了转移性结直肠癌中对尼沃卢马布加上伊皮利穆马布的反应. 炎症标志物有利于单独使用尼沃卢马布,而瘤突变负担和微卫星不稳定性有利于组合治疗.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 基因组学就是基因组学.
背景情况:
- 尼沃卢马布和伊皮利穆马布在微卫星不稳定性高/不匹配修复缺陷的转移性结直肠癌中显示出益处.
- 生物标志物驱动的治疗选择可以优化免疫治疗的疗效.
研究的目的:
- 探索与nivolumab (单独或与ipilimumab) 疗效相关的组织生物标志物,用于先前治疗的MSI-H/dMMR mCRC.
- 调查炎症或瘤抗原性是否预测对不同免疫疗法方案的反应.
主要方法:
- 从第二阶段的CheckMate 142研究中进行的探索性生物标记分析.
- 评估基因表达特征,瘤突变负担,英德尔负担和微卫星不稳定性.
主要成果:
- 较高的炎症标志与尼沃卢马布单独治疗的更好的反应和存活率相关.
- 更高的瘤突变负担,英德尔负担和MSI与尼沃卢马布加上伊皮利穆马布的更好的反应和生存相关.
- 这些发现表明,瘤抗原性可能是组合疗法疗效的关键.
结论:
- 生物标志物概况可能有助于区分MSI-H/dMMRmCRC的最佳免疫疗法策略.
- 在组合治疗中,瘤抗原性似乎比基线炎症更为关键.
- 需要在更大的随机试验中进一步验证.
相关概念视频
Tumor Immunotherapy
1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
Combination Therapies and Personalized Medicine
5.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.8K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
447
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
447
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
604
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
604
Drugs for Treatment of Ulcerative Colitis in IBD
413
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
413
Inflammatory Bowel Disease IV: Pharmacological Management
427
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
427


